Technical Analysis for NTLA - Intellia Therapeutics, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| F | 13.12 | -7.15% | -1.01 |
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| New 52 Week Closing Low | Bearish | 0.00% | |
| New 52 Week Low | Weakness | 0.00% | |
| Outside Day | Range Expansion | 0.00% | |
| Below Lower BB | Weakness | 0.00% | |
| Lower Bollinger Band Touch | Weakness | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| New Downtrend | Bearish | -7.15% | |
| NR7 | Range Contraction | -7.15% | |
| Narrow Range Bar | Range Contraction | -7.15% | |
| Inside Day | Range Contraction | -7.15% |
| Alert | Time |
|---|---|
| Lower Bollinger Band Support | about 16 hours ago |
| Down 1 ATR | about 17 hours ago |
| 60 Minute Opening Range Breakdown | about 20 hours ago |
| Down 5% | about 20 hours ago |
| Fell Below Lower Bollinger Band | about 20 hours ago |
Get a Trading Assistant
- Earnings date: 11/07/2024
Intellia Therapeutics, Inc. Description
Intellia Therapeutics Inc., a gene editing company, focuses on the development of therapeutics utilizing a biological tool known as the CRISPR/Cas9 system. The company develops in vivo programs focused on liver diseases, including transthyretin amyloidosis, alpha-1 antitrypsin deficiency, hepatitis B virus, and inborn errors of metabolism; and ex vivo applications of the technology in chimeric antigen receptor T cell and hematopoietic stem cell product candidates. It has a strategic collaboration and license agreement with Novartis focused on the development of new ex vivo CRISPR/Cas9-based therapies. Intellia Therapeutics Inc. was formerly known as AZRN, Inc. and changed its name to Intellia Therapeutics Inc. in July 2014. The company was founded in 2014 and is headquartered in Cambridge, Massachusetts.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biotechnology Biology Immune System Emerging Technologies Molecular Biology Genetics Hepatitis B Precision Medicine Liver Disease Metabolism Amyloid Amyloidosis Chimeric Antigen Receptor T Cell Chimeric Antigen Receptor Hepatitis B Virus CRISPR Antitrypsin Deficiency Genome Editing Hematopoietic Stem Cell Cell Product Inborn Errors Of Metabolism Cas9 Transthyretin Transthyretin Amyloidosis
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 34.87 |
| 52 Week Low | 12.82 |
| Average Volume | 2,470,605 |
| 200-Day Moving Average | 23.17 |
| 50-Day Moving Average | 18.26 |
| 20-Day Moving Average | 15.33 |
| 10-Day Moving Average | 15.35 |
| Average True Range | 1.17 |
| RSI (14) | 31.03 |
| ADX | 26.61 |
| +DI | 15.44 |
| -DI | 36.90 |
| Chandelier Exit (Long, 3 ATRs) | 17.67 |
| Chandelier Exit (Short, 3 ATRs) | 16.32 |
| Upper Bollinger Bands | 17.52 |
| Lower Bollinger Band | 13.14 |
| Percent B (%b) | -0.01 |
| BandWidth | 28.52 |
| MACD Line | -1.18 |
| MACD Signal Line | -1.06 |
| MACD Histogram | -0.1292 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 15.30 | ||||
| Resistance 3 (R3) | 15.44 | 14.85 | 14.93 | ||
| Resistance 2 (R2) | 14.85 | 14.30 | 14.78 | 14.81 | |
| Resistance 1 (R1) | 13.99 | 13.96 | 13.70 | 13.85 | 14.69 |
| Pivot Point | 13.40 | 13.40 | 13.26 | 13.33 | 13.40 |
| Support 1 (S1) | 12.54 | 12.85 | 12.25 | 12.40 | 11.55 |
| Support 2 (S2) | 11.95 | 12.51 | 11.88 | 11.43 | |
| Support 3 (S3) | 11.09 | 11.95 | 11.31 | ||
| Support 4 (S4) | 10.95 |
